drugset / Trial / NCT05578092
A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase 1, open-label, multicenter, study evaluating the safety, tolerability, PK, PD, and anti-tumor activity of MRTX0902 alone and in combination with MRTX849 (adagrasib) in patients with advanced solid tumor malignancy harboring mutations in the KRAS-MAPK pathways.
Timeline
- Start
- 2022-12-02
- Primary completion
- 2026-02-03
- Completion
- 2026-02-03
Outcome
Outcome not reported
Stopped (Business): “business objectives have changed”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adagrasib | Small molecule | — | — |
| Subject | MRTX0902 | Small molecule | — | — |